Safety of brigatinib following alectinib-induced-pneumonitis: Case report
Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs.We report a case of a patient with ALK positi...
Saved in:
Main Authors: | Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007124001837 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01) -
Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
by: Kyuhwan Kim, et al.
Published: (2025-02-01) -
Targeting HVEM-GPT2 axis: a novel approach to T cell activation and metabolic reprogramming in non-small cell lung cancer therapy
by: Yuanshan Yao, et al.
Published: (2025-02-01) -
CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer
by: Qian Dai, et al.
Published: (2024-12-01) -
A rare case of vision loss caused by leptomeningeal metastasis of lung adenocarcinoma: a case report and literature review
by: Zhihua Li, et al.
Published: (2025-02-01)